Subscribe

Future Directions in Myeloma

February 2012 Vol 5, No 1, Special Issue - Multiple Myeloma, Multiple Myeloma
Caroline Helwick
Caroline Helwick
Table
Novel Investigational Agents for Multiple Myeloma

With so many new myeloma drugs of various classes in the pipeline (Table), “myeloma is going to become a chronic ill­ness, with sustained complete responses in a significant fraction of patients,” according to Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston.

In his ASH 2011 presentation about treatment targets and niches, Dr Ander­son predicted that the future direction of multiple myeloma man­­age­­ment will include:

  • Development of immune treat­ments (vaccine and adoptive im­muno­therapy); these may be very personalized
  • Development of novel agents aimed at the myeloma cell in the bone marrow microenvironment; these will target cell growth, survival, and drug resistance
  • Development of rationally based combination therapies, such as bortezomib plus histone deacetylase inhibitors
  • Utilization of genomics for im­proved classification; microRNA profiles can already identify clinical subgroups with different survival outcomes
  • Personalized treatment based on tumor genetics.

Sonja Zweegman, MD, PhD, of VU University Medical Center, Am­ster­dam, and Erasmus University, Rotterdam, the Netherlands, moderated the session on new agents in myeloma. She elaborated on the future of personalized treatment for myeloma: “We need many drugs to prolong the life of these patients, and what you will increasingly see happen is the use of biologically determined treatment.”

For example, she said, we heard here at ASH 2011, that with the MEK (mitogen-activated protein kinase kinase) inhibitor AZD6244 (selumetinib), only patients with activation of the signaling transduction pathway will respond.

“It will help to have a biological determination of the malignant plasma cells, and a predictive model to help select the most appropriate treatment for a particular patient. That will be the future,” said Dr Zweegman. 

Dr Anderson agreed. “With whole genome sequencing coming, and with so many novel agents—including many in phase 3 trials, as we saw discussed at this meeting—I know the future is bright in myeloma.”

Related Items
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on August 17, 2020 in Multiple Myeloma
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue published on February 25, 2020 in Multiple Myeloma
Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma
Phoebe Starr
February 2020 Vol 13, Special Issue published on February 25, 2020 in Multiple Myeloma
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Yvette Florio Lane
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 27, 2019 in FDA Approvals, Multiple Myeloma, In the News
Last modified: March 16, 2012
Copyright © Engage Healthcare Communications, LLC. All rights reserved.